Previous studies revealed that two multigene expression-based assays, the Oncotype DX 21-gene recurrence score [7–9] and the MammaPrint 70-gene signature [10, 11], can predict chemotherapy benefit for patients with hormone receptor-positive early breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.